MedPageToday -- ORLANDO -- Men with early-stage prostate cancer had almost a 40% reduction in the risk of progression when treated with the drug dutasteride (Avodart) during active surveillance, according to data from a randomized trial.
MedPageToday -- ORLANDO -- Men with early-stage prostate cancer had almost a 40% reduction in the risk of progression when treated with the drug dutasteride (Avodart) during active surveillance, according to data from a randomized trial.